<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943081</url>
  </required_header>
  <id_info>
    <org_study_id>PCNL in chronic kidney disease</org_study_id>
    <nct_id>NCT04943081</nct_id>
  </id_info>
  <brief_title>Percutaneous Nephrolithotomy in Patients With Stage 2-4 Chronic Kidney Disease</brief_title>
  <official_title>The Effect of Percutaneous Nephrolithotomy on the Estimated Glomerular Filtration Rate in Patients With Stage 2-4 Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effect of percutaneous nephrolithotomy (PCNL) on estimated&#xD;
      glomerular filtration rate (eGFR) in patients with stage 2-4 chronic kidney disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nephrolithiasis affects an estimated 5-10% of the general population, and this percentage&#xD;
      continues to rise. It has a prevalence of 1.7% to 18% in patients with chronic kidney disease&#xD;
      (CKD), and nephrolithiasis-related CKD contributed to 3.2% of the total patients who started&#xD;
      maintenance dialysis therapy.&#xD;
&#xD;
      The etiology of renal insufficiency in patients with nephrolithiasis is multifactorial and&#xD;
      includes renal obstruction, recurrent urinary tract infections, frequent surgical&#xD;
      interventions and coexisting medical disease.&#xD;
&#xD;
      According to National kidney foundation, chronic kidney disease is classified into 5 stages&#xD;
      as follows:&#xD;
&#xD;
      Stage 1: Kidney damage with normal or elevated GFR &lt; 90 ml/min/1.7 m2 Stage 2: Kidney damage&#xD;
      with mildly decreased GFR 60-89 ml/min/1.7 m2 Stage 3: Moderately decreased GFR 30-59&#xD;
      ml/min/1.7 m2 Stage 4: Severely decreased GFR 15-29 ml/min/1.7 m2 Stage 5: Kidney Failure&#xD;
      GFR&gt;15 ml/min/1.7 m2 Management of nephrolithiasis in patients with CKD is often difficult.&#xD;
      Options for preserving kidney function include watchful waiting, shockwave lithotripsy (SWL),&#xD;
      an endourologic approach (Percutaneous nephrolithotomy or retrograde intra-renal surgery),&#xD;
      laparoscopic surgery or conventional open surgery.&#xD;
&#xD;
      Percutaneous nephrolithotomy (PCNL) is considered as the gold standard intervention for large&#xD;
      burden and complex renal stone disease and is associated with the highest stone free rates&#xD;
      (SFRs). However, potentially significant complications include bleeding, sepsis, pleural and&#xD;
      visceral injury. Therefore, the optimal management plan needs to be tailored to individual&#xD;
      patient.&#xD;
&#xD;
      Serum creatinine level has been used as a crude index of renal function in studies of&#xD;
      patients with CKD, but it is not reliable. The glomerular filtration rate (GFR) should be&#xD;
      used instead. GFR is the most accurate way to give health providers an estimate of&#xD;
      functioning renal mass. Estimating GFR with the use of prediction equations is cost&#xD;
      effective.&#xD;
&#xD;
      In this study, we will prospectively evaluate the effect of percutaneous nephrolithotomy on&#xD;
      the estimated glomerular filtration rate in Patients With Stage 2-4 chronic kidney disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of GFR for all patients pre-operative</measure>
    <time_frame>1 day pre-operative</time_frame>
    <description>Estimation of GFR for all patients pre-operative by using body surface area based-Cockcroft-Gault formula (CG/ BSA).&#xD;
Body surface area based Cockcroft-Gault formula (CG/ BSA) = [(140- age) x weight in kilograms x (0.85 if female)] / (72 x serum creatinine in mg/dl).&#xD;
This formula expects weight to be measured in kilograms and creatinine to be measured in mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimation of GFR for all patients three months post-operative</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Estimation of GFR for all patients three months post-operative by using body surface area based-Cockcroft-Gault formula (CG/ BSA).&#xD;
Body surface area based Cockcroft-Gault formula (CG/ BSA) = [(140- age) x weight in kilograms x (0.85 if female)] / (72 x serum creatinine in mg/dl).&#xD;
This formula expects weight to be measured in kilograms and creatinine to be measured in mg/dl.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Percutaneous Nephrolithotomy</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous nephrolithotomy</intervention_name>
    <description>Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope</description>
    <arm_group_label>Case group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with&#xD;
             pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic renal failure on regular dialysis.&#xD;
&#xD;
          -  Patients with bleeding diathesis.&#xD;
&#xD;
          -  Patients who are unfit for surgery.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients who are refusing the participation in our study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adel Kurkar</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Moeen</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amr Abo-Faddan</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Abdelghany</last_name>
    <phone>+201021474046</phone>
    <email>m.abdelghany746@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Edvardsson VO, Indridason OS, Haraldsson G, Kjartansson O, Palsson R. Temporal trends in the incidence of kidney stone disease. Kidney Int. 2013 Jan;83(1):146-52. doi: 10.1038/ki.2012.320. Epub 2012 Sep 19. Erratum in: Kidney Int. 2013 May;83(5):972.</citation>
    <PMID>22992468</PMID>
  </reference>
  <reference>
    <citation>Gupta M, Bolton DM, Gupta PN, Stoller ML. Improved renal function following aggressive treatment of urolithiasis and concurrent mild to moderate renal insufficiency. J Urol. 1994 Oct;152(4):1086-90.</citation>
    <PMID>8072069</PMID>
  </reference>
  <reference>
    <citation>Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004 Nov;44(5):799-805.</citation>
    <PMID>15492945</PMID>
  </reference>
  <reference>
    <citation>Gambaro G, Favaro S, D'Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis. 2001 Feb;37(2):233-43. Review.</citation>
    <PMID>11157364</PMID>
  </reference>
  <reference>
    <citation>National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.</citation>
    <PMID>11904577</PMID>
  </reference>
  <reference>
    <citation>Gopalakrishnan G, Prasad GS. Management of urolithiasis with chronic renal failure. Curr Opin Urol. 2007 Mar;17(2):132-5. Review.</citation>
    <PMID>17285024</PMID>
  </reference>
  <reference>
    <citation>Jones P, Aboumarzouk OM, Rai BP, Somani BK. Percutaneous Nephrolithotomy for Stones in Solitary Kidney: Evidence From a Systematic Review. Urology. 2017 May;103:12-18. doi: 10.1016/j.urology.2016.10.022. Epub 2016 Nov 14. Review.</citation>
    <PMID>27856206</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Abdelghany Allam</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

